Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $3,413 | 1 | 98.7% |
| Food and Beverage | $46.00 | 1 | 1.3% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $3,413 | 1 | $0 (2024) |
| Averitas Pharma Inc. | $46.00 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,413 | 1 | Eli Lilly and Company ($3,413) |
| 2023 | $46.00 | 1 | Averitas Pharma Inc. ($46.00) |
All Payment Transactions
2 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 07/25/2024 | Eli Lilly and Company | — | — | In-kind items and services | $3,412.50 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) | ||||||
| 09/05/2023 | Averitas Pharma Inc. | QUTENZA (Drug) | Food and Beverage | In-kind items and services | $46.00 | General |
| Category: PAIN MANAGEMENT | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) | Eli Lilly and Company | $3,413 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 13 | 831 | 1,264 | $502,814 | $110,384 |
| 2022 | 12 | 857 | 1,375 | $560,080 | $124,835 |
| 2021 | 14 | 1,034 | 1,642 | $688,938 | $143,134 |
| 2020 | 15 | 1,064 | 1,901 | $763,931 | $162,155 |
All Medicare Procedures & Services
69 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 62323 | Injection of substance into lower spine canal using imaging guidance | Facility | 2023 | 269 | 538 | $177,002 | $43,217 | 24.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 78 | 98 | $42,952 | $8,811 | 20.5% |
| 64493 | Injection of lower or sacral spine facet joint using imaging guidance, single level | Facility | 2023 | 47 | 76 | $40,964 | $8,298 | 20.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 81 | 81 | $36,243 | $7,843 | 21.6% |
| 62321 | Injection of substance into middle or upper spine canal using imaging guidance | Facility | 2023 | 53 | 90 | $32,400 | $7,713 | 23.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 44 | 44 | $24,772 | $6,084 | 24.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 53 | 61 | $20,108 | $4,780 | 23.8% |
| 64490 | Injection of upper or middle spine facet joint using imaging guidance, single level | Facility | 2023 | 23 | 35 | $22,190 | $4,208 | 19.0% |
| 64635 | Destruction of lower or sacral spinal facet joint nerves using imaging guidance, single facet joint | Facility | 2023 | 14 | 18 | $23,094 | $4,103 | 17.8% |
| 64494 | Injection of lower or sacral spine facet joint using imaging guidance, second level | Facility | 2023 | 37 | 65 | $19,240 | $4,038 | 21.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 50 | 53 | $16,377 | $3,526 | 21.5% |
| 64491 | Injection of upper or middle spine facet joint using imaging guidance, second level | Facility | 2023 | 20 | 30 | $16,650 | $2,123 | 12.8% |
| 27096 | Injection of anesthetic or steroid into joint between lower spine and hip bone using imaging guidance | Facility | 2023 | 15 | 20 | $9,880 | $1,656 | 16.8% |
| 64483 | Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, single level | Facility | 2023 | 11 | 15 | $9,960 | $1,565 | 15.7% |
| 64636 | Destruction of lower or sacral spinal facet joint nerves using imaging guidance, each additional facet joint | Facility | 2023 | 14 | 18 | $6,120 | $1,243 | 20.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 22 | 22 | $4,862 | $1,175 | 24.2% |
| 62323 | Injection of substance into lower spine canal using imaging guidance | Facility | 2022 | 260 | 546 | $179,634 | $45,353 | 25.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 120 | 120 | $53,520 | $13,303 | 24.9% |
| 64493 | Injection of lower or sacral spine facet joint using imaging guidance, single level | Facility | 2022 | 65 | 111 | $59,829 | $12,300 | 20.6% |
| 64635 | Destruction of lower or sacral spinal facet joint nerves using imaging guidance, single facet joint | Facility | 2022 | 30 | 33 | $42,339 | $7,706 | 18.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 47 | 87 | $38,019 | $7,493 | 19.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 77 | 87 | $28,602 | $7,094 | 24.8% |
| 62321 | Injection of substance into middle or upper spine canal using imaging guidance | Facility | 2022 | 45 | 77 | $27,720 | $6,968 | 25.1% |
| 64494 | Injection of lower or sacral spine facet joint using imaging guidance, second level | Facility | 2022 | 62 | 107 | $31,672 | $6,894 | 21.8% |
| 64490 | Injection of upper or middle spine facet joint using imaging guidance, single level | Facility | 2022 | 34 | 56 | $35,504 | $6,690 | 18.8% |
About Dr. Christopher Wenger, MD
Dr. Christopher Wenger, MD is a Interventional Pain Medicine healthcare provider based in Westwood, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/21/2005. The National Provider Identifier (NPI) number assigned to this provider is 1255317210.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Christopher Wenger, MD has received a total of $3,459 in payments from pharmaceutical and medical device companies, with $3,413 received in 2024. These payments were reported across 2 transactions from 2 companies. The most common payment nature is "" ($3,413).
As a Medicare-enrolled provider, Wenger has provided services to 3,786 Medicare beneficiaries, totaling 6,182 services with total Medicare billing of $540,507. Data is available for 4 years (2020–2023), covering 69 distinct procedure/service records.
Practice Information
- Specialty Interventional Pain Medicine
- Other Specialties Anesthesiology
- Location Westwood, MA
- Active Since 12/21/2005
- Last Updated 04/23/2024
- Taxonomy Code 208VP0014X
- Entity Type Individual
- NPI Number 1255317210
Products in Payments
- QUTENZA (Drug) $46.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.